Hosted on MSN1mon
Sanofi gets FDA approval for NovoLog insulin biosimilarrapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus. The FDA approved 3 mL single-patient-use prefilled pen and 10 mL ...
NovoLog is also available in pen injector formats. Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris ...
The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart ... than $55 for a box of five pen cartridges – which Civica ...
It calls the new drug “Merilog,” a biosimilar to the widely-used insulin product Novolog (insulin aspart ... single-patient-use prefilled pen and a 10-milliliter multiple-dose vial.
The US Food and Drug Administration (FDA) approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart ... single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose ...
Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin ... use prefilled pen and a 10 milliliter ...
Study design. This prospective, randomized, controlled, parallel-group study compared the use of pen devices with conventional vials and syringes for the administration of insulin in hospitalized ...
Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results